Ron Bentsur
Overview
Ron Bentsur received an average of $2M in total compensation, including $518K in salary, at Nuvectis Pharma between 2022 and 2023. Ron Bentsur also received an average of $2M at UroGen Pharma Ltd. from 2016 to 2019 and an average of $3M at Keryx Biopharmaceuticals from 2006 to 2015.
- 2023
- 2022
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
- 2012
Nuvectis PharmaPresident & Chief Executive Officer
Nuvectis PharmaPresident & Chief Executive Officer
UroGen Pharma Ltd.Former Chief Executive Officer
UroGen Pharma Ltd.Former Chief Executive Officer
UroGen Pharma Ltd.Former Chief Executive Officer
UroGen Pharma Ltd.Former Chief Executive Officer
Keryx BiopharmaceuticalsFormer Chief Executive Officer
Keryx BiopharmaceuticalsFormer Chief Executive Officer
Keryx BiopharmaceuticalsFormer Chief Executive Officer
Keryx BiopharmaceuticalsFormer Chief Executive Officer
Source: SEC filings on April 29, 2024, April 29, 2020, April 26, 2019, April 15, 2016, April 30, 2015, October 10, 2014, April 30, 2013, April 30, 2012, and April 30, 2007.
Related executives
We found 24 more executives who work or worked at Nuvectis Pharma, UroGen Pharma Ltd., andKeryx Biopharmaceuticals.
Enrique Poradosu
Nuvectis Pharma
Chief Scientific & Business Officer
Shay Shemesh
Nuvectis Pharma
Chief Development & Operations Officer
Elizabeth Barrett
UroGen Pharma Ltd.
Chief Executive Officer
Jason Smith
UroGen Pharma Ltd.
General Counsel
Don Kim
UroGen Pharma Ltd.
Chief Financial Officer
Molly Henderson
UroGen Pharma Ltd.
Chief Financial Officer
Peter Pfreundschuh
UroGen Pharma Ltd.
Chief Financial Officer
Mark Schoenberg
UroGen Pharma Ltd.